Search Results

You are looking at 251 - 260 of 524 items for :

  • "Adjuvant therapy" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Outcomes Following Neoadjuvant Chemotherapy for Breast Cancer in Women Aged 40 Years and Younger: Impact of Pathologic Nodal Response

Margaret M. Kozak, Clare E. Jacobson, Rie von Eyben, Erqi L. Pollom, Melinda Telli, and Kathleen C. Horst

adjuvant treatment to improve outcomes, and several trials have evaluated escalation of adjuvant therapy. 16 – 18 The recently published CREATE-X trial 19 evaluated 910 patients with HER2-negative breast cancer who had residual invasive disease or LN

Full access

Updates in the Treatment of Metastatic Colorectal Cancer

Presented by: Midhun Malla, Katrina S. Pedersen, and Aparna R. Parikh

neoadjuvant arm. 7 The neoadjuvant arm involved administering oxaliplatin and fluorouracil or capecitabine for 6 weeks, followed by surgery, and then up to a perioperative total of 3 versus 6 months of adjuvant therapy. This trial revealed that patients with

Full access

Non–Small Cell Lung Cancer: Recommendations for Biomarker Testing and Treatment

Presented by: Dara L. Aisner and Gregory J. Riely

NCCN Guidelines now list osimertinib as an option for adjuvant therapy in patients with resectable stage IIB–IIIA or high-risk stage IB–IIA NSCLC harboring EGFR mutations who received previous adjuvant chemotherapy or are ineligible to receive

Full access

Gastric and Esophageal Cancers: Guidelines Updates

Presented by: Crystal S. Denlinger, Kristina A. Matkowskyj, and Mary F. Mulcahy

-free survival, there was clear benefit for nivolumab as adjuvant therapy (22.4 vs 11.0 months; HR, 0.69; P =.0003), with the benefit sustained over time. Nivolumab was favored in all subgroups. “This is the most robust data we have seen showing any benefit

Full access

Personalized Medicine and Oncology Practice Guidelines: A Case Study of Contemporary Biomarkers in Colorectal Cancer

Robin K. Kelley, Stephanie L. Van Bebber, Kathryn A. Phillips, and Alan P. Venook

tumor specimens of patients enrolled in randomized studies of adjuvant 5-fluorouracil with levamisole or leucovorin compared with no adjuvant therapy. 98 This study showed no improvement in overall survival in patients with stage II and III colon cancer

Full access

Predictors of Guideline Treatment Nonadherence and the Impact on Survival in Patients With Colorectal Cancer

Robert B. Hines, Alina Barrett, Philip Twumasi-Ankrah, Dominique Broccoli, Kimberly K. Engelman, Joaquina Baranda, Elizabeth A. Ablah, Lisette Jacobson, Michelle Redmond, Wei Tu, and Tracie C. Collins

and the decreasing likelihood of receiving neoadjuvant/adjuvant therapy. 42 , 43 , 47 A reason for these findings has been the increasing prevalence of comorbid disease in older age groups. Consistent with the literature, 10 , 38 , 42 , 43 , 47 – 52

Full access

Integration of Systemic and Liver-Directed Therapies for Locally Advanced Hepatocellular Cancer: Harnessing Potential Synergy for New Therapeutic Horizons

Eric H. Bent, Eric Wehrenberg-Klee, Eugene J. Koay, Lipika Goyal, and Jennifer Y. Wo

individually been evaluated in the neoadjuvant and adjuvant settings with mixed results. 74 – 77 At this time, the guidelines of the AASLD and the European Association for the Study of the Liver do not recommend neoadjuvant or adjuvant therapy in most patients

Full access

Treating Elderly Patients With Muscle-Invasive Bladder Cancer

Elizabeth R. Kessler, Janet B. Kukreja, Christopher L. Geiger, and Stacy M. Fischer

toxicity calculator, then they may opt for surgical resection and discussion of the role of adjuvant therapy based on the pathologic risk identified at the time of surgery. Table 2. Criteria for Cisplatin Ineligibility For patients who do not receive NAC

Full access

Radiation Therapy in Operable and Locally Advanced Pancreatic Cancer

Andrew H. Ko and Christopher H. Crane

relative importance of chemotherapy and radiation as adjuvant therapy ( Table 1 ). The ESPAC-1 trial, 2 conducted by the European Study Group for Pancreatic Cancer, used a 2-by-2 factorial design in which patients were randomly assigned after surgery to 1

Full access

High-Grade Glioma/Glioblastoma Multiforme: Is There a Role for Photodynamic Therapy?

Harry T. Whelan

children treated in the CCG-945 study. No evidence was seen that temozolomide given during radiotherapy and as an adjuvant therapy resulted in improved event-free survival compared with that found in CCG-945. 4 In addition, temozolomide failed to improve